Study finds no significant benefit of spironolactone in HFpEF or HFmrEF

A trial testing the aldosterone blocker spironolactone in patients with heart failure with preserved ejection fraction (HFpEF ...
MedPage Today

Novel Antihypertensive Reduced Blood Pressure in Primary Aldosteronism

Current treatment options for primary aldosteronism are limited to surgery or mineralocorticoid receptor antagonists when surgery isn't an option. In a phase IIa trial, baxdrostat resolved or reduced ...
Medical Dialogues

Epidural anesthesia linked to Cardioprotective Effects mediated by Aldosterone Suppression: Study

A new study published in the journal of Anesthesiology Research and Practice showed that the cardioprotective advantages of ...
STAT

Can a new class of drugs finally control hypertension in millions of patients?

In this Q&A, Mineralys CEO Jon Congleton discusses how targeting aldosterone could reshape hypertension treatment. Aldosterone synthase inhibitors (ASIs) are drawing a lot of attention. What first ...
Seeking Alpha

Mineralys Therapeutics, Inc. (MLYS) Presents at H.C. Wainwright 27th Annual Global Investment Conference Prepared Remarks Transcript

There we go. I'll be making forward-looking statements for the course of the day. So as I noted, Mineralys is focused on how do we target aldosterone in cardiorenal metabolic disorders. We do that ...